Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineNeutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus proteinAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.Triaryl pyrazoline compound inhibits flavivirus RNA replication.Antibody Recognition and Neutralization Determinants on Domains I and II of West Nile Virus Envelope ProteinPre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse modelEpitope Determinants of a Chimpanzee Dengue Virus Type 4 (DENV-4)-Neutralizing Antibody and Protection against DENV-4 Challenge in Mice and Rhesus Monkeys by Passively Transferred Humanized AntibodyType- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent EpitopesHumanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In VivoDengue virus-specific murine T-lymphocyte proliferation: serotype specificity and response to recombinant viral proteinsSemliki Forest virus E2 envelope epitopes induce a nonneutralizing humoral response which protects mice against lethal challengeAntibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing)Yellow fever vaccine induces integrated multilineage and polyfunctional immune responsesProgress on the development of therapeutics against West Nile virusThe Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverIdentification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.Pathocenosis: a holistic approach to disease ecologyCD8+ T cells complement antibodies in protecting against yellow fever virus.Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.A DNA vaccine against yellow fever virus: development and evaluation.A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse modelDengue vaccine: priorities and progress.Yellow fever vaccine.Development of effective therapies against West Nile virus infection.Hemagglutinin-esterase-specific monoclonal antibodies alter the neuropathogenicity of mouse hepatitis virusProgress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach.The molecular basis of antibody-mediated neutralization of West Nile virus.Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis.Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.Biomarkers in Japanese encephalitis: a review.Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model.A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from diseaseThe early cellular signatures of protective immunity induced by live viral vaccination.
P2860
Q24289014-F92136DF-03D0-4C27-B9D6-70532F496D00Q26782367-665B73EC-F0B0-4388-AB0C-2E6EB874D4CCQ27469558-AECEA518-2E36-462C-8085-29D6A59357FDQ27469855-319F0E66-A5D0-421A-A264-72EC23D10724Q27473103-063F12E7-AD27-40D9-8BE8-2AA9DFFD4B49Q27473130-3482443B-1C52-47DA-89A6-0543575D046DQ27477718-A1B5877D-166C-4010-BB96-B656F97AFC11Q27480808-C5C2BE5C-1FED-44F7-9242-7644B1145B90Q27485025-64EFC12F-8517-4BF6-8607-75971668EF4EQ27485031-3D216812-4090-41B3-9C1A-CE5FDE637345Q27486404-89553250-73E7-4B4D-B728-59BA1829EFD6Q27486616-798F1BDC-7B06-43FD-A410-3043E3FBB90FQ27486623-1FEADA1A-2306-4C7A-A78C-A71F696129DFQ27486833-0B0ADA9F-0738-45E1-A531-C2AA654CD87EQ27487514-79CBCE4C-4034-4045-9A81-B789932521CDQ27489893-53A9D45C-3E1E-4F3E-967D-CB07773A9BE1Q27491317-10F362F2-83B3-44E6-95F1-2EA6951ECC4EQ28740522-44ABDC23-2F29-44B9-97A5-FE9C733D5D0BQ33201423-B6E01AE0-CE09-443E-8F6D-F1772B2D49B8Q33610555-8EAD1D37-D4EC-45B2-A897-83F8931B27CBQ34420281-6429B017-DE57-4DA1-9FB7-1B276AF77589Q34980404-F155D5FF-75BD-4CAE-8A4A-96DD677E192DQ35141448-5B676ACC-93A5-4543-8D56-ACD3224A9E8EQ35392195-17160181-891B-45CD-A02B-EDD6DE1B678FQ35881790-4433B185-18EF-4F35-9D0D-F1E26453E62EQ35886309-B7D0C910-012D-4BF3-A48D-C3F0976141B0Q35903209-1F694FD6-CBF3-46ED-A2FB-5F745953654EQ35964754-C6370E09-A5E3-4F01-A7BA-108C7B5687DEQ36238729-23D64E2C-B12C-41BC-B584-7F7499A5B70CQ36322125-B531D05D-B995-4E66-AAD0-A40479FD9F9EQ36697370-C7E9D592-190F-4C99-AD1B-6A805D43CC01Q36825107-336BBEEB-0D75-48E9-8D28-91710F985B6DQ36842733-04CBA067-CD0C-4A22-9233-91599000F3DDQ37136479-A60989F8-D6A8-4747-8E15-E4F90AA0F834Q37336551-3E176268-8D19-448C-8D4E-92B37E4FCE84Q37423499-C0A6569E-40AD-4496-B823-87AA618C23F3Q37425963-5A175566-9E1E-4C47-8C62-E482453EB6CDQ37634164-BA2C6984-9CD7-4274-9812-EBF801E53838Q39811978-BECBCCE2-3567-4543-B5B0-36FD10646492Q40282359-58C2E4C7-A9EA-4081-98A8-C39E0C6223F7
P2860
Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Lethal 17D yellow fever enceph ...... ow fever and dengue 2 viruses.
@en
type
label
Lethal 17D yellow fever enceph ...... ow fever and dengue 2 viruses.
@en
prefLabel
Lethal 17D yellow fever enceph ...... ow fever and dengue 2 viruses.
@en
P2093
P921
P1476
Lethal 17D yellow fever enceph ...... ow fever and dengue 2 viruses.
@en
P2093
Brandriss MW
Briselli M
P304
P356
10.1099/0022-1317-67-2-229
P407
P478
67 ( Pt 2)
P577
1986-02-01T00:00:00Z